Stem Cells News and Research

RSS

Stem cells have the remarkable potential to develop into many different cell types in the body during early life and growth. In addition, in many tissues they serve as a sort of internal repair system, dividing essentially without limit to replenish other cells as long as the person or animal is still alive. When a stem cell divides, each new cell has the potential either to remain a stem cell or become another type of cell with a more specialized function, such as a muscle cell, a red blood cell, or a brain cell.

New technique to treat metabolic disorders in babies while still in the womb

Researchers say a new development in cord blood transplants for inherited metabolic disorders may be curative for some babies who are treated while still in the womb.

20 Oct 2009

Article evaluating StemEx therapy for leukemia and lymphoma to be published

Gamida Cell announced today the publication of an article evaluating carlecortemcel-l, the generic name of what is widely known as "StemEx", as a therapy for blood cancers such as leukemia and lymphoma.

19 Oct 2009

Rich Plasma and Stem Cell therapies improve orthopedic conditions

Although stem cells sounds innovative and cutting edge, this therapy has been around for quite some time. In today's advanced medical climate stem cells are being used to treat many orthopedic conditions including osteoarthritis of the hip knee and shoulder, partial tears of tendons, muscles, and ligaments including rotator cuff tears, and various back conditions including disc herniations.

19 Oct 2009

Stem cell treatments could repair the kidney defects associated with Alport syndrome

Several cell-based therapy approaches could provide new treatments for patients with Alport syndrome, reports an upcoming paper in the Journal of the American Society of Nephrology (JASN). "Our study opens up many considerations of how new therapies related to the use of stem cells can be devised for our kidney patients with chronic disease," comments Raghu Kalluri, MD, PhD (Harvard Medical School, Boston, MA).

19 Oct 2009

Researchers find the genetic mutation that is linked with changes in brain development

For decades, scientists have thought the faulty neural wiring that predisposes individuals to behavioral disorders like autism and psychiatric diseases like schizophrenia must occur during development. Even so, no one has ever shown that a risk gene for the disease actually disrupts brain development.

19 Oct 2009

Ethics in biomedical research: One-year grant from NIH to develop interactive educational software

Arkitek Studios and the Northwest Association for Biomedical Research (NWABR) have been awarded a $100,000 Phase I Small Business Innovation Research (SBIR) grant from the National Center for Research Resources, a component of the National Institutes of Health. This one-year grant, entitled ETHOS (Ethics Training Health Oriented Software), provides funding for development of interactive educational software that will underscore the critical role ethics plays in biomedical research.

19 Oct 2009

DKC establishes link between genetic mutation affecting telomerase function and human disease

The human genetic disease dyskeratosis congenita (DKC) is an autosomal dominant disease that leads to abnormalities in tissues with a rapid cell turnover - the skin, nails, bone marrow, lungs and gut. Patients with DKC experience life-threatening symptoms. Bone marrow failure increases their risk of fatal infections and cancer. Many die before the age of 30 and management of the disease is limited to trying to treat its symptoms.

19 Oct 2009

DFG Research Centre to be funded for a further four-year period

The DFG Research Centre for Renewable Therapies at the Technical University of Dresden ("Renewable Therapies: From Cells to Tissues to Therapies - Engineering the Cellular Basis of Regeneration ", CRTD), following a very successful first funding period, is being extended and will be funded for a further four years.

19 Oct 2009

Institute Curie Hospital in France adds another TomoTherapy radiation therapy system

TomoTherapy Incorporated announced today that the Institute Curie Hospital in France has purchased a second TomoTherapy® radiation therapy system, to support the increasing demand for intensity-modulated radiation therapy (IMRT). The Institute Curie Hospital has been treating cancer patients with TomoTherapy technology since March 2007, when it became the first hospital in France to adopt the technology.

19 Oct 2009

Research study provides supportive evidence for using ATR inhibitors in cancer therapy

A study published in the October issue of Nature Genetics demonstrates that loss of the tumor-suppressor protein p53, coupled with elimination of the DNA-maintenance protein ATR, severely disrupts tissue maintenance in mice.

19 Oct 2009

Fate Therapeutics announces human iPSC generation using a combination of small molecules

Fate Therapeutics, Inc. announced today the generation of human induced-pluripotent stem cells (iPSCs) using a combination of small molecules that significantly improves the speed and efficiency of reprogramming.

19 Oct 2009

Findings provide new insight on skin pigmentation

The skin's pigment cells can be formed from completely different cells than has hitherto been thought, a new study from the Swedish medical university Karolinska Institutet shows. The results, which are published in the journal Cell, also mean the discovery of a new kind of stem cell.

19 Oct 2009

Access Pharmaceuticals' update on its European commercial launch of Mugard

ACCESS PHARMACEUTICALS, INC. today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and chemotherapy.

15 Oct 2009

Soligenix commences enrollment in its Phase 3 Orbec clinical trial for acute GI GVHD

Soligenix, Inc., formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today that it has initiated enrollment in its confirmatory Phase 3 randomized, double-blind, placebo-controlled, multicenter clinical trial evaluating orBec(®) for the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD).

15 Oct 2009

Cord Blood America addresses shareholder questions regarding its new laboratory in Las Vegas

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells, a biological insurance policy for families nationwide and internationally, today addressed shareholder questions about its new laboratory in Las Vegas in an interview of Matthew Schissler, founder and CEO, by analyst Francis Gaskins.

15 Oct 2009

New maintenance medium for human embryonic and pluripotent stem cells

STEMCELL Technologies Inc. (STEMCELL) is pleased to announce the release of TeSR™2, a defined, animal-protein free maintenance medium for human embryonic and induced pluripotent stem cells. This medium takes a step towards addressing the needs of researchers working towards the culture of their cells in a medium free of animal-derived proteins.

15 Oct 2009

MSU receives $6.2 million Morris K. Udall Center of Excellence for Parkinson's disease grant

A team of researchers from Michigan State University and the University of Cincinnati have been awarded a $6.2 million Morris K. Udall Center of Excellence for Parkinson's disease grant.

15 Oct 2009

Cytheris initiates Phase I/IIa dose escalation study of patients suffering from ICL

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of a Phase I/IIa dose escalation study of patients suffering from idiopathic CD4 lymphocytopenia (ICL).

15 Oct 2009

Medtronic announces results of study comparing INFUSE Bone Graft to autogenous bone graft

Medtronic, Inc. today announced results of a study comparing the safety and effectiveness of INFUSE® Bone Graft to autogenous bone graft (bone harvested from the patient) when used in maxillary sinus floor augmentation.

14 Oct 2009

Research scientists develop bioengineered treatment for targeting pancreatic cancer

Research scientists from Massachusetts General Hospital, Boston, have developed a novel bioengineered treatment that has shown promise in targeting pancreatic cancer without causing damage to healthy noncancer cells, a typical problem of chemotherapy.

14 Oct 2009

Stem Cells News and Research

Further Reading

New technique to treat metabolic disorders in babies while still in the womb

Article evaluating StemEx therapy for leukemia and lymphoma to be published

Rich Plasma and Stem Cell therapies improve orthopedic conditions

Stem cell treatments could repair the kidney defects associated with Alport syndrome

Researchers find the genetic mutation that is linked with changes in brain development

Ethics in biomedical research: One-year grant from NIH to develop interactive educational software

DKC establishes link between genetic mutation affecting telomerase function and human disease

DFG Research Centre to be funded for a further four-year period

Institute Curie Hospital in France adds another TomoTherapy radiation therapy system

Research study provides supportive evidence for using ATR inhibitors in cancer therapy

Fate Therapeutics announces human iPSC generation using a combination of small molecules

Findings provide new insight on skin pigmentation

Access Pharmaceuticals' update on its European commercial launch of Mugard

Soligenix commences enrollment in its Phase 3 Orbec clinical trial for acute GI GVHD

Cord Blood America addresses shareholder questions regarding its new laboratory in Las Vegas

New maintenance medium for human embryonic and pluripotent stem cells

MSU receives $6.2 million Morris K. Udall Center of Excellence for Parkinson's disease grant

Cytheris initiates Phase I/IIa dose escalation study of patients suffering from ICL

Medtronic announces results of study comparing INFUSE Bone Graft to autogenous bone graft

Research scientists develop bioengineered treatment for targeting pancreatic cancer

Event guide: 7th Allogeneic Cell Therapies Summit eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo